DOCSLIB.ORG

Advanced Solutions for Advanced Pathology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advanced Solutions for Advanced Pathology Advanced Solutions for Advanced Pathology Molecular Morphology Reference Guide 2014 Contents Active Immunostainer . 3 ImPath36 Benefits . 4 ImPath36 Specifications . 12 ImPath RFID Antibodies . 12 Antibodies for Immunohistochemistry . 15 Categorical Index . 16 Antibody Product Details . 19 Product Index . 242 Ordering Information . 245 Active Immunostainer Active Immunostainer 3 Advanced Solutions for Advanced Pathology Active Immunostainer Active Immunostainer The importance of Molecular Morphology to achieve precise dia- gnoses and Patient’s stratification in oncology is constantly evolving. This has an impact on the anatomic pathology lab requiring broader, optimised and more standardised Molecular Morphology tests. Today the main challenge is to expand the standardisation achie- ved in immunohistochemistry, extending automation of more com- plex tests, while optimising workflow. 4 Advanced Solutions for Advanced Pathology Advanced Solutions for Advanced Pathology I’m is the Advanced Solution for molecular morphology. A uni- que and complete system combining a next generation instrument with a world class range of antibodies and probes. The Advanced Solution is a breakthroughfor the pathology lab. I’m Flexibility optimising the workload based on needs I’m Relief standardising the workflow through automation I’m Efficiency accelerating processes without shortcuts I’m Environmentally Friendly reducing waste impact and optimising the work space. 5 Active Immunostainer Active Immunostainer I’m Flexibility Protocol flexibility slide by slide. No more boundaries Different applications per single run (Immunocytochemistry tests. FISH/CISH tests, Immunohistochemistry long/short protocols) Flexibility 6 Advanced Solutions for Advanced Pathology Advanced Solutions for Advanced Pathology I’m Relief Standardising the workflow thanks to complete automation, from dewax to counterstain, allowing full walk-away capabilities Ensuring an efficient use of reagents by the Plug-n-Play Radio Frequency Identification (PnP RFID) tracking system Sharing information by a multi platform network, connected to a Laboratory Interface Management System (LIMS) Relief 7 Active Immunostainer Active Immunostainer I’m Efficiency Delivering same day diagnosis by performing enhanced FISH protocols in less than 5 hours Protese + Dewax HR Hybridization Stringency Denaturation 20 25 5 10 min 1h min min 14 h min Protese + Dewax HR Hybridization Stringency Denaturation 20 25 5 10 min 1h min min 3,5 h min FISH Protocol < 5H Providing Clinicians with fast, reliable reports Efficiency 8 Advanced Solutions for Advanced Pathology Advanced Solutions for Advanced Pathology I’m Environmental friendly Reducing waste generation considerably with separate toxic waste Being a ‘bench-system’ that optimises the workspace thanks to its reduced dimensions 69,2 cm 93,4 cm 68 cm Competitor 1 Competitor 2 Environmental friendly 9 Active Immunostainer I’mFlexibility Relief Efficiency FRE10 Advanced Solutions for Advanced Pathology yyEEnnvivirroonnmemenntatal flr iefriendndly ly EE EE11 Active Immunostainer ImPath36 Reference 43965 Dimensions 91 .44 cm x 60 .96 cm x 53 .34 cm Weight 49 .9 kg Electrical requirements 220V 220/240V (±10%) 50Hz (±2Hz) 700 Normal operating temperature 18°C-26°C Slide capacity 1-36 glass slides Reagent capacity 40 different reagents (15 mL/reagent vial) Reagent dispense volumes 85-400 μL Reagent probe volume capacity 20 μL minimum, 4500μL maximum Printer Zebra TLP 3844-Z or Zebra GX430t Computer controller requirements 1.2GHz Intel Pentium® processor, A . Menarini Diagnostics reserves the right to change 4 MB RAM, 320 GB hard drive, the computer controller specifications at any time USB 2 .0 Communications Port Compliance CE IVD Directive 98/79/EC ImPath RFID Antibodies 45122 IMPATH A-1-Antichymotrypsin RTU R (Poly) 45171 IMPATH Calponin-1 RTU R (EP798Y) 45123 IMPATH A-1-Antitrypsin RTU R (Poly) 45172 IMPATH Calretinin RTU R (Poly) 45161 IMPATH ACTH RTU R (Poly) 45176 IMPATH CD1A RTU R (EP3622) 45235 IMPATH Actin Muscle Specific RTU M (HHF35) 45177 IMPATH CD2 RTU M (MRQ-11) 45121 IMPATH Actin Smooth Muscle RTU M (1A4) 45179 IMPATH CD3 (MRQ-39) 45162 IMPATH ALK Protein RTU M (ALK-1) 45277 IMPATH CD4 RTU R (EP204) 45163 IMPATH Alpha-Fetoprotein RTU R (Poly) 45133 IMPATH CD5 RTU R (EP77) 45164 IMPATH Androgen Receptor RTU M (SP107) 45188 IMPATH CD7 RTU M (MRQ-56) 45290 IMPATH Annexin A1 RTU M (MRQ-3) 45191 IMPATH CD8 RTU M (C8/144B) 45291 IMPATH Arginase-1 RTU R (SP156) 45125 IMPATH CD10 RTU M (56C6) 45293 IMPATH BCA-225 RTU M (Cu-18) 45126 IMPATH CD11c RTU M (5D11) 45165 IMPATH BCL2 RTU M (E17) 45646 IMPATH CD13 RTU R (SP187) 45166 IMPATH BCL6 RTU M (GI191E/A8) 45274 IMPATH CD14 RTU R (EPR3653) 45167 IMPATH Beta-Catenin RTU M (14) 45174 IMPATH CD15 RTU M (MMA) 45294 IMPATH BG8 RTU M (F3) 45647 IMPATH CD16 RTU R (SP175) 45124 IMPATH BOB-1 RTU R (SP92) 45175 IMPATH CD19 RTU M (MRQ-36) 45295 IMPATH C3d RTU R (Poly) 45128 IMPATH CD20 RTU M (L26) 45296 IMPATH C4d RTU R (SP91) 45275 IMPATH CD21 RTU R (EP3093) 45168 IMPATH CA-125 RTU M (OC125) 45178 IMPATH CD23 RTU M (1B12) 45692 IMPATH CA19-9 RTU M (121SLE) 45129 IMPATH CD25 RTU M (4C9) 45645 IMPATH Cadherin-17 RTU R (SP183) 45180 IMPATH CD30 RTU M (Ber-H2) 45170 IMPATH Calcitonin RTU R (Poly) 45181 IMPATH CD31 RTU M (JC70) 45272 IMPATH Caldesmon RTU R (E89) 45130 IMPATH CD33 RTU M (PWS44) 12 Advanced Solutions for Advanced Pathology ImPath RFID Antibodies 45131 IMPATH CD34 RTU M (QBEnd/10) 45648 IMPATH Ep-CAM RTU M (Ber-EP4) 45182 IMPATH CD35 RTU M (RLB25) 45141 IMPATH EP-CAM RTU M (MOC-31) 45276 IMPATH CD38 RTU R (SP149) 45206 IMPATH Epstein-Barr Virus RTU M (MRQ-47) 45183 IMPATH CD43 RTU M (MT1) 45284 IMPATH Estrogen Receptor RTU R (EP1) 45184 IMPATH CD44 RTU M (MRQ-13) 45207 IMPATH Factor VIII RTU R (Poly) 45185 IMPATH CD45 RTU M (2B11 & PD7/26) 45208 IMPATH Factor XIIIa RTU R (EP3372) 45297 IMPATH CD45R RTU M (MB1) 45209 IMPATH Fascin RTU M (55k-2) 45132 IMPATH CD45RO RTU M (UCHL-1) 45303 IMPATH FLI-1 RTU M (MRQ-1) 45186 IMPATH CD56 RTU R (MRQ-42) 45216 IMPATH FSH RTU R (Poly) 45134 IMPATH CD57 RTU M (NK-1) 45142 IMPATH Galectin-3 RTU M (9C4) 45135 IMPATH CD61 RTU M (2f2) 45143 IMPATH Gastrin RTU R (Poly) 45136 IMPATH CD63 RTU M (NKI/C3) 45652 IMPATH GATA3 RTU M (L50-823) 45187 IMPATH CD68 RTU M (Kp-1) 45285 IMPATH GCDFP-15 RTU R (EP1582Y) 45189 IMPATH CD71 RTU M (MRQ-48) 45210 IMPATH GH RTU R (Poly) 45137 IMPATH CD74 RTU M (LN2) 45144 IMPATH GFAP RTU R (EP672Y) 45190 IMPATH CD79a RTU M (JCB117) 45145 IMPATH Glucagon RTU R (Poly) 45192 IMPATH CD99 RTU R (EPR3097Y) 45305 IMPATH GLUT1 RTU R (Poly) 45273 IMPATH CD117 RTU R (YR145) 45306 IMPATH Glycophorin A RTU M (GA-R2) 45173 IMPATH CD138 RTU M (B-A38) 45307 IMPATH Glypican-3 RTU M (1G12) 45127 IMPATH CD163 RTU M (MRQ-26) 45211 IMPATH Granzyme B RTU R (Poly) 45278 IMPATH CDX-2 RTU R (EPR2764Y) 45148 IMPATH Hcg RTU R (Poly) 45194 IMPATH CEA RTU M (CEA31) 45146 IMPATH Helicobacter pylori RTU R (Poly) 45193 IMPATH CEA RTU R (Poly) 45286 IMPATH HEMOGLOBIN A RTU R (EPR3608) 45195 IMPATH Chromogranin A RTU M (LK2H10) 45212 IMPATH Hepatitis B Virus Core RTU R (Poly) RUO 45298 IMPATH Claudin 1 RTU R (Poly) 45213 IMPATH Hepatitis B Virus Surface RTU M (S1-210) RUO 45203 IMPATH CMV RTU M (8B1.2,1G5.2&2D4.2) 45147 IMPATH Hepatocyte Specific Antigen RTU M (OCH1E5) 45196 IMPATH Collagen Type IV RTU M (CIV22) 45649 IMPATH Her2/Neu RTU R (EP3) 45279 IMPATH COX-2 RTU R (SP21) 45214 IMPATH Herpes Simplex Virus I RTU R (PolY) 45280 IMPATH Cyclin D1 RTU R (EP12) 45215 IMPATH Herpes Simplex Virus II RTU R (Poly) 45138 IMPATH Cytokeratin RTU M (34betaE12) 45311 IMPATH HGAL RTU M (MRQ-49) 45201 IMPATH Cytokeratin 8 RTU M (35betaH11) 45153 IMPATH HMB-45 RTU M (HMB-45) 45299 IMPATH Cytokeratin RTU M (OSCAR) 45318 IMPATH HMB-45&MART-1 RTU M (HMB-45&MelanA) 45197 IMPATH Cytokeratin 14 RTU M (LL002) 45312 IMPATH Hpl RTU R (Poly) 45198 IMPATH Cytokeratin 17 RTU M (Ks 17 .E3) 45217 IMPATH IgA RTU R (Poly) 45199 IMPATH Cytokeratin 19 RTU M (A53-B/A2 .26) 45218 IMPATH IgD RTU R (Poly) 45139 IMPATH Cytokeratin 20 RTU M (Ks20 .8) 45219 IMPATH IgG RTU R (Poly) 45300 IMPATH Cytokeratin 5&6 RTU M (D5 & 16B4) 45313 IMPATH IgG4 RTU M (MRQ-44) 45281 IMPATH Cytokeratin 5 RTU R (EP1601Y) 45220 IMPATH IgM RTU R (Poly) 45693 IMPATH CK5 + CK14 RTU M (EP1601Y & LL002) 45221 IMPATH Inhibin alpha RTU M (R1) 45200 IMPATH Cytokeratin 7 RTU M (OV-TL 12/30) 45314 IMPATH INI-1 RTU M (MRQ-27) 45202 IMPATH Cytokeratin 8 & 18 RTU M (B22 .1 & B2) 45222 IMPATH Insulin RTU G (Poly) 45140 IMPATH Cytokeratin Cocktail RTU M (AE1 & AE3) 45150 IMPATH Kappa RTU M (L1C1) 45301 IMPATH Cytokeratin HMW RTU M (AE3) 45319 IMPATH KBA .62 RTU M (KBA .62) 45302 IMPATH Cytokeratin LMW RTU M (AE1) 45287 IMPATH Ki-67 RTU R (EP5) 45204 IMPATH Desmin RTU M (D33) 45315 IMPATH Ksp-cadherin RTU M (MRQ-33) 45283 IMPATH E-cadherin RTU R (EP700Y) 45223 IMPATH Lambda Light Chain RTU M (Lamb14) 45205 IMPATH EMA RTU M (E29) 45224 IMPATH LH RTU R (Poly) 13 Active Immunostainer ImPath RFID Antibodies 45316 IMPATH LMO2 RTU R (SP51) 45327 IMPATH Podoplanin RTU M (D2-40) 45151 IMPATH Lysozyme RTU R (Poly) 45289 IMPATH Progesterone Receptor RTU R (Y85) 45225 IMPATH Macrophage RTU M (HAM-56) 45328 IMPATH Prolactin RTU R (Poly) 45317 IMPATH Mammaglobin RTU R (31A5) 45254 IMPATH PSA RTU M (ER-PR8) RUO 45152 IMPATH MART-1 (Melan A) RTU M (A103) 45255 IMPATH PSAP RTU M (PASE/4LJ) 45226 IMPATH MITF RTU M (C5/D5) 45329 IMPATH PU .1 RTU R (EPR3158Y) 45227 IMPATH MLH1 RTU M (G168-728) 45257 IMPATH Renal Cell Carcinoma RTU M (PN-15) 45228 IMPATH MSH2 RTU M
Load more

Recommended publications
  • Molecular Mechanisms of Neuroimmune Crosstalk in the Pathogenesis of Stroke
    International Journal of Molecular Sciences Review Molecular Mechanisms of Neuroimmune Crosstalk in the Pathogenesis of Stroke Yun Hwa Choi 1, Collin Laaker 2, Martin Hsu 2, Peter Cismaru 3, Matyas Sandor 4 and Zsuzsanna Fabry 2,4,* 1 School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA; [email protected] 2 Neuroscience Training Program, University of Wisconsin-Madison, Madison, WI 53705, USA; [email protected] (C.L.); [email protected] (M.H.) 3 Chemistry, University of Wisconsin-Madison, Madison, WI 53705, USA; [email protected] 4 Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA; [email protected] * Correspondence: [email protected] Abstract: Stroke disrupts the homeostatic balance within the brain and is associated with a significant accumulation of necrotic cellular debris, fluid, and peripheral immune cells in the central nervous system (CNS). Additionally, cells, antigens, and other factors exit the brain into the periphery via damaged blood–brain barrier cells, glymphatic transport mechanisms, and lymphatic vessels, which dramatically influence the systemic immune response and lead to complex neuroimmune communi- cation. As a result, the immunological response after stroke is a highly dynamic event that involves communication between multiple organ systems and cell types, with significant consequences on not only the initial stroke tissue injury but long-term recovery in the CNS. In this review, we discuss the complex immunological and physiological interactions that occur after stroke with a focus on how the peripheral immune system and CNS communicate to regulate post-stroke brain homeostasis. First, Citation: Choi, Y.H.; Laaker, C.; Hsu, we discuss the post-stroke immune cascade across different contexts as well as homeostatic regulation M.; Cismaru, P.; Sandor, M.; Fabry, Z.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0026032 A1 ZUBERY Et Al
    US 2008.0026.032A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0026032 A1 ZUBERY et al. (43) Pub. Date: Jan. 31, 2008 (54) COMPOSITE IMPLANTS FOR PROMOTING Publication Classification BONE REGENERATION AND (51) Int. Cl. AUGMENTATION AND METHODS FOR A6F 2/00 (2006.01) THER PREPARATION AND USE A638/00 (2006.01) A6IP 9/00 (2006.01) (76) Inventors: Yuval ZUBERY, Cochav Yair (52) U.S. Cl. ............................................ 424/423: 514/2 (IL); Arie Goldlust, Ness Ziona (57) ABSTRACT (IL); Thomas Bayer, Tel-Aviv (IL); Eran Nir, Rehovot (IL) Collagen based matrices cross-linked by a reducing Sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two Correspondence Address: layers including reducing Sugar cross-linked collagen matri DANEL, SWIRSKY ces of different densities. The composite matrices may be 55 REUVEN ST. used in bone regeneration and/or augmentation applications. BET SHEMESH 99.544 Scaffolds including glycated and/or reducing Sugar cross linked collagen exhibit improved support for cell prolifera (21) Appl. No.: 11/829,111 tion and/or growth and/or differentiation. The denser col lagen matrix of the composite matrices may have a dual effect initially functioning as a cell barrier and later func (22) Filed: Jul. 27, 2007 tioning as an ossification Supporting layer. The composite matrices, implants and scaffolds may be prepared using different collagen types and collagen mixtures and by cross Related U.S. Application Data linking the collagen(s) using a reducing Sugar or a mixture (60) Provisional application No. 60/833,476, filed on Jul.
    [Show full text]
  • Basic Structure of the Villous Trees
    6 Basic Structure of the Villous Trees M. Castellucci and P. Kaufmann Nearly the entire maternofetal and fetomaternal exchange Syncytiotrophoblast takes place in the placental villi. There is only a limited contribution to this exchange by the extraplacental mem- Syncytium or Multinucleated Giant Cells? branes. In addition, most metabolic and endocrine activi- The syncytiotrophoblast is a continuous, normally unin- ties of the placenta have been localized in the villi (for terrupted layer that extends over the surfaces of all villous review, see Gröschel-Stewart, 1981; Miller & Thiede, 1984; trees as well as over parts of the inner surfaces of chori- Knobil & Neill, 1993; Polin et al., 2004). onic and basal plates. It thus lines the intervillous Throughout placental development, different types of space. Systematic electron microscopic studies of the syn- villi emerge that have differing structural and functional cytial layer (e.g., Bargmann & Knoop, 1959; Schiebler & specializations. Despite this diversification, all villi exhibit Kaufmann, 1969; Boyd & Hamilton, 1970; Kaufmann the same basic structure (Fig. 6.1): & Stegner, 1972; Schweikhart & Kaufmann, 1977; Wang • They are covered by syncytiotrophoblast, an epithelial & Schneider, 1987) have revealed no evidence that the surface layer that separates the villous interior from syncytiotrophoblast is composed of separate units. Rather, the maternal blood, which flows around the villi. Unlike it is a single continuous structure for every placenta. Only other epithelia, the syncytiotrophoblast is not com- in later stages of pregnancy, as a consequence of focal posed of individual cells but represents a continuous, degeneration of syncytiotrophoblast, fibrinoid plaques uninterrupted, multinucleated surface layer without may isolate small islands of syncytiotrophoblast from the separating cell borders (Fig.
    [Show full text]
  • [Thesis Title Goes Here]
    THE USE OF A TISSUE ENGINEERED MEDIA EQUIVALENT IN THE STUDY OF A NOVEL SMOOTH MUSCLE CELL PHENOTYPE A Dissertation Presented to The Academic Faculty by JoSette Leigh Briggs Broiles In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in Bioengineering Georgia Institute of Technology April 2008 COPYRIGHT 2008 BY JOSETTE LEIGH BRIGGS BROILES THE USE OF A TISSUE ENGINEERED MEDIA EQUIVALENT IN THE STUDY OF A NOVEL SMOOTH MUSCLE CELL PHENOTYPE Approved by: Dr. Robert M. Nerem, Advisor Dr. Thomas N. Wight School of Mechanical Engineering Hope Heart Program Georgia Institute of Technology Benaroya Research Institute at Virginia Mason Department of Pathology University of Washington Dr. Raymond P. Vito Dr. Elliot Chaikof School of Mechanical Engineering Department of Biomedical Engineering Georgia Institute of Technology Georgia Institute of Technology and Emory University Dr. W. Robert Taylor Department of Biomedical Engineering Georgia Institute of Technology and Emory University Date Approved: December 18, 2007 to Yvette Louise Briggs, the perfect example of a wife-mother-student ACKNOWLEDGEMENTS Before I proceed with my long list of thank-you’s, I must praise God for blessing me with the opportunity to pursue a Ph.D. and surrounding me with wonderful people that have encouraged me throughout this process. My tenure at Georgia Tech has been quite a challenging voyage. This was the first time I experienced repeated failures, was not at the top of the class, and not in complete control of my fortune. I’ve often said that in high school I learned how to navigate social pressures and in undergrad I discovered the meaning of true friendship.
    [Show full text]
  • Tamm-Horsfall Glycoprotein Enhances PMN Phagocytosis by Binding to Cell Surface-Expressed Lactoferrin and Cathepsin G That Activates MAP Kinase Pathway
    Molecules 2011, 16, 2119-2134; doi:10.3390/molecules16032119 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Tamm-Horsfall Glycoprotein Enhances PMN Phagocytosis by Binding to Cell Surface-Expressed Lactoferrin and Cathepsin G That Activates MAP Kinase Pathway Syue-Cian Siao 1, Ko-Jen Li 2, Song-Chou Hsieh 2, Cheng-Han Wu 2, Ming-Chi Lu 3, Chang-Youh Tsai 4 and Chia-Li Yu 1,2,* 1 Institute of Molecular Medicine, National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei 100, Taiwan 2 Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei 100, Taiwan 3 Division of Allergy, Immunology and Rheumatology, Buddhist Dalin Tzu-Chi General Hospital, No. 2 Ming-Shen Road, Dalin, Chia-Yi, Taiwan 4 Section of Allergy, Immunology and Rheumatology, Taipei-Veterans General Hospital, No. 201 Section 2, Shih-Pai Road, Taipei 11217, Taiwan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +886-2-23123456 Ext.65011; Fax: +886-2-23957801. Received: 7 December 2010; in revised form: 15 February 2011 / Accepted: 28 February 2011 / Published: 3 March 2011 Abstract: The molecular basis of polymorphonuclear neutrophil (PMN) phagocytosis-enhancing activity (PEA) by human purified urinary Tamm-Horsfall glyco- protein (THP) has not been elucidated. In this study, we found human THP bound to lactoferrin (LF) and cathepsin G (CG) expressed on the surface of PMN, identified by a proteomic study with MALDI-TOF- LC/LC/mass spectrometric analysis.
    [Show full text]
  • Immunohistochemistry Reference Guide, Vol
    Immunohistochemistry reference guide, vol. 10 New Products CD71 (MRQ-48) Androgen Receptor (SP107) . 13 CD23 (MRQ-57) . 46 Arginase-1 (SP156) . 15 CD23 (SP23) . 46 BCL2 (SP66) . 18 CD33 (PWS44) . 50 BCL6 (SP155) . 19 CD38 (SP149) . 53 BOB.1 (SP92) . 22 CD43 (SP55) . 54 C3d (polyclonal) . 23 CD56 (MRQ-42) . 59 C4d (SP91) . 24 CD71 (MRQ-48) . 64 Calcitonin (SP17) . 27 CD79a (SP18) . 66 Calretinin (SP13) . 30 CD99 (SP119) . 67 Carbonic Anhydrase IX (CA IX) CD138 (SP152) . 69 (MRQ-54 (also known as M75)) . 31 CMV (8B1 .2, 1G5 .2 & 2D4 .2) . 75 CD1a (EP3622‡) . 32 Cytokeratin 14 (SP53) . 86 CD3 (MRQ-39) . 34 Diamond TBS Antibody Diluent . 231 CD7 (MRQ-56) . 37 Epstein-Barr Virus (MRQ-47) . 99 CD8 (SP16) . 38 FoxP1 (SP133) . .105 CD11c (5D11) . 40 Hemoglobin A (EPR3608‡) . 119 CD20 (SP32) . 44 Her2/Neu (SP3) . 123 S100P (16/f5) Herpes Simplex Virus I (10A3) . 124 Progesterone Receptor (SP42) . 192 HGAL (MRQ-49) . 126 S100P (16/f5) . 199 IgG4 (MRQ-44) . 134 Smoothelin (R4A) . .200 KBA.62 . 140 SOX-2 (SP76) . 202 LMO2 (SP51) . 145 SOX-11 (MRQ-58) . 203 MSH6 (SP93) . 155 Synaptophysin (MRQ-40) . .206 MUM1 (MRQ-43) . 160 T-bet (MRQ-46) . 207 Myeloperoxidase (SP72) . .162 TBS IHC Wash Buffer + Tween® 20 . 231 Napsin A (MRQ-60) . 166 TdT (SP150) . 210 NSE (MRQ-55) . 169 TFE3 (MRQ-37) . 211 p53 (SP5) . .174 Thyroglobulin (MRQ-41) . .213 PAX-8 (MRQ-50) . .182 TIA-1 (EP243‡) . .214 PAX-8 (polyclonal) . .182 Uroplakin III (SP73) . 221 PBS IHC Wash Buffer + Tween® 20 . 231 Varicella Zoster Virus (multiple clones) .
    [Show full text]
  • 2021 Clinical Diagnostic Laboratory Fee Schedule CPT Codes, Descriptions and Other Data Only Are Copyright 2021 American Medical Association
    2021 Clinical Diagnostic Laboratory Fee Schedule CPT codes, descriptions and other data only are copyright 2021 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association (AMA). YEAR HCPCS MOD EFF_DATE INDICATOR RATE2021 SHORTDESC LONGDESC 2021 0001U 20210101 N 00720.00 Rbc dna hea 35 ag 11 bld grp Red blood cell typing 2021 0002M 20210101 N 00503.40 Liver dis 10 assays w/ash Liver disease, ten biochemical assays (alt, a2-macroglobulin, apolipoprotein 2021 0002U 20210101 N 00025.00 Onc clrct 3 ur metab alg plp Measurement of substances in urine to predict likelihood of polyps in large 2021 0003M 20210101 N 00503.40 Liver dis 10 assays w/nash Liver disease, ten biochemical assays (alt, a2-macroglobulin, apolipoprotein 2021 0003U 20210101 N 00950.00 Onc ovar 5 prtn ser alg scor Measurement of proteins associated with ovarian cancer in serum 2021 0004M 20210101 N 00079.00 Scoliosis dna alys Scoliosis, dna analysis of 53 single nucleotide polymorphisms (snps), using 2021 0005U 20210101 N 00760.00 Onco prst8 3 gene ur alg Test for detecting genes associated with prostate cancer in urine 2021 0006M 20210101 N 00150.00 Onc hep gene risk classifier Oncology (hepatic), mrna expression levels of 161 genes, utilizing fresh 2021 0007M 20210101 N 00375.00 Onc gastro 51 gene nomogram Oncology (gastrointestinal neuroendocrine tumors), real-time pcr expression 2021 0007U 20210101 N 00114.43 Rx test prsmv ur w/def conf Testing for presence of drug in urine 2021 0008U 20210101 N 00597.91 Hpylori
    [Show full text]
  • 2020 Clinical Diagnostic Laboratory Fee Schedule CPT Codes, Descriptions and Other Data Only Are Copyright 2018 American Medical Association
    2020 Clinical Diagnostic Laboratory Fee Schedule CPT codes, descriptions and other data only are copyright 2018 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association (AMA). Codes in green are enddated. NOTE: Zero pay (0.00) codes will be reimbursed at 65% of billed charges ** The appearance on this schedule of a code and rate is not an indication of coverage , nor a guarantee of payment. HCPCS MODIFIER SHORT DESCRIPTION RATE 2020 End Date 0001U Rbc dna hea 35 ag 11 bld grp $720.00 0002M Liver dis 10 assays w/ash $503.40 0002U Onc clrct 3 ur metab alg plp $25.00 0003M Liver dis 10 assays w/nash $503.40 0003U Onc ovar 5 prtn ser alg scor $950.00 0004M Scoliosis dna alys $79.00 0005U Onco prst8 3 gene ur alg $760.00 0006M Onc hep gene risk classifier $150.00 0006U Detc ia meds 120+ analytes $246.92 0007M Onc gastro 51 gene nomogram $375.00 0007U Rx test prsmv ur w/def conf $114.43 0008U Hpylori detcj abx rstnc dna $597.91 0009U Onc brst ca erbb2 amp/nonamp $107.00 0010U Nfct ds strn typ whl gen seq $427.26 0011M Onc prst8 ca mrna 12 gen alg $760.00 0011U Rx mntr lc-ms/ms oral fluid $114.43 0012M Onc mrna 5 gen rsk urthl ca $760.00 0012U Germln do gene reargmt detcj $2,515.60 0013M Onc mrna 5 gen recr urthl ca $760.00 0013U Onc sld org neo gene reargmt $2,515.60 0014U Hem hmtlmf neo gene reargmt $2,515.60 0016U Onc hmtlmf neo rna bcr/abl1 $163.96 0017U Onc hmtlmf neo jak2 mut dna $91.66 0018U Onc thyr 10 microrna seq alg $3,002.09 0019U Onc rna tiss predict alg $3,675.00 0021U
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,652,507 B2 Kizer Et Al
    US008652507 B2 (12) United States Patent (10) Patent No.: US 8,652,507 B2 Kizer et al. (45) Date of Patent: *Feb. 18, 2014 (54) JUVENILE CARTILAGE COMPOSITION (56) References Cited (75) Inventors: Neil Kizer, Crestwood, MO (US); U.S. PATENT DOCUMENTS Robert Spiro, Half Moon Bay, CA (US); 1,347,622 A 7/1920 Deininger Jian Yao, Austin, TX (US); Cheryl 2,533,004 A 12/1950 Ferry et al. Renee Blanchard, Warsaw, IN (US) 2,621,145 A 12/1952 Sano 3,400,199 A 9, 1968 Balassa 3,474,146 A 10, 1969 Baker et al. (73) Assignee: Zimmer, Inc., Warsaw, IN (US) 3,476,855 A 11/1969 Balassa 3,478,146 A 11/1969 Balassa (*) Notice: Subject to any disclaimer, the term of this 3,772,432 A 11/1973 Balassal patent is extended or adjusted under 35 RE28,093 E 7, 1974 Balassa 3,966,908 A 6, 1976 Balassa U.S.C. 154(b) by 43 days. 4,440,680 A 4, 1984 Cioca This patent is Subject to a terminal dis 4,453,939 A 6, 1984 Zimmerman et al. claimer. 4,479,271 A 10/1984 Bolesky et al. 4,522,096 A 6/1985 Niven, Jr. 4,566,138 A 1/1986 Lewis et al. (21) Appl. No.: 12/976,711 4,587,766 A 5/1986 Miyatake et al. (22) Filed: Dec. 22, 2010 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2012/OOO9224A1 Jan. 12, 2012 AU 1998.71003 B2 10, 1998 AU 2006282754 A2 3, 2007 (Continued) Related U.S.
    [Show full text]
  • Expanding the Chondroitin Sulfate Glycoproteome — but How Far?
    fcell-09-695970 August 9, 2021 Time: 12:32 # 1 MINI REVIEW published: 13 August 2021 doi: 10.3389/fcell.2021.695970 Expanding the Chondroitin Sulfate Glycoproteome — But How Far? Fredrik Noborn1*, Mahnaz Nikpour1, Andrea Persson1, Jonas Nilsson1,2 and Göran Larson1 1 Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden, 2 Proteomics Core Facility, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden Chondroitin sulfate proteoglycans (CSPGs) are found at cell surfaces and in connective tissues, where they interact with a multitude of proteins involved in various pathophysiological processes. From a methodological perspective, the identification of CSPGs is challenging, as the identification requires the combined sequencing of specific core proteins, together with the characterization of the CS polysaccharide modification(s). According to the current notion of CSPGs, they are often considered in relation to a functional role in which a given proteoglycan regulates a specific function in cellular physiology. Recent advances in glycoproteomic methods have, however, enabled the identification of numerous novel chondroitin sulfate core proteins, and their glycosaminoglycan attachment sites, in humans and in various animal models. Edited by: John Whitelock, In addition, these methods have revealed unexpected structural complexity even in University of New South Wales, the linkage regions. These findings indicate that the number and structural complexity Australia of CSPGs are much greater than previously perceived. In light of these findings, the Reviewed by: prospect of finding additional CSPGs, using improved methods for structural and Jasmeen S. Merzaban, King Abdullah University of Science functional characterizations, and studying novel sample matrices in humans and in and Technology, Saudi Arabia animal models is discussed.
    [Show full text]
  • 20.310J Molecular, Cellular, and Tissue Biomechanics
    Cardiovascular Tissues Musculoskeletal Tissues Courtesy of Ernst B. Hunziker. Used with permission. © source unknown. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. 1 Musculoskeletal Tissues Tension Compression & Shear © ADAM, Inc. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. 2 Tendon Pro-collagen molecule _ © Taylor & Francis Group. All rights reserved. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/. Source: Kastelic, J., A. Galeski, et al. "The Multicomposite Structure of Tendon." Connective Tissue Research 6, no. 1 (1978): 11-23. E~1 GPa Force - extension Fit by WLC model Courtesy of Elsevier, Inc., http://www.sciencedirect.com. Used with permission. Source: Gutsmann, Thomas. "Force Spectroscopy of Collagen Fibers to Investigate their Mechanical Properties and Structural Organization." Biophysical Journal 86, no. 5 (2004): 3186-93. Stress vs strain curve of a rat tail tendon: (A-B) Toe - heel region, (Sun+, J Biomechanics, 2004) (C) linear region, (D) plateau, Courtesy of Elsevier, Inc., http://www.sciencedirect.com. Used with permission. (E) rupture of the tendon. Source: Sun, Yu-Long, et al. "Stretching Type II Collagen with Optical Tweezers." Journal of Biomechanics 37, no. 11 (2004): 1665-9. (Gutsmann+, Biophys J, 2004) 3 Cell ~ 60μm long Intracellular Fibricarrier Protruding Fibripositor © source unknown. All rights reserved. This content is excluded from our Creative Courtesy of Karl E. Kadler. Used with permission.
    [Show full text]
  • Structure and Biology of the Intervertebral Disk in Health and Disease
    Structure and Biology of the Intervertebral Disk in Health and Disease Wilson C.W. Chan, PhDa, Kit Ling Sze, PhDa, Dino Samartzis, DScb, Victor Y.L. Leung, PhDc, Danny Chan, PhDa,* KEYWORDS Intervertebral disk Degeneration Extracellular matrix Development Biology Low back pain is a leading debilitating condition sixth and seventh decade of life.24,25 However, that affects every population worldwide,1 and the development or, rather, severity of IVD degen- can lead to diminished physical function, loss of eration is not linearly based on age; degenerative wages, decreased quality of life, and psycholog- changes can be noted in young children and not ical distress.1–4 In fact, chronic low back pain yet be manifested in other adults.19,24 Overall, the may also lead to brain tissue destruction.5–8 As true prevalence of IVD degeneration in populations a consequence, low back pain is one of the most has yet to be determined, due to improper surveil- common conditions for which to seek medical lance methods (ie, patient-based versus consultation and one of those preeminent for anal- population-based), sampling issues, heterogeneity gesic use in the United States.3,4 Furthermore, the in the operational definition and imaging modalities management of patients with low back pain can be in assessing the phenotype of disk changes, and an a challenge, often requiring a multidisciplinary incomplete understanding of the risk-factor profile approach to treatment (see the article by Karppi- and its interaction effects that may affect degener- nen and colleagues elsewhere in this issue).9–13 ative changes and their manifestation in different Although low back pain is a multifactorial condi- age, gender, and ethnic groups.14,15,26 Along these tion (eg, biopsychological, muscular, socioeco- lines, the incidence rates of annular tears, disk nomic), intervertebral disk (IVD) degeneration has bulging, and endplate defects/abnormalities are been indicated to be a strong etiologic factor also not conclusive, and vary between studies.
    [Show full text]